Product Description
QN-302 is potentially a first-in-class small molecule drug candidate with superior efficacy and activity against pancreatic cancer compared to existing agents, with a distinct mechanism of action and preclinical target profile. (Sourced from: https://www.qualigeninc.com/pipeline/qn-302/)
Mechanisms of Action: G4 Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral, Intravenous
FDA Designation: Orphan Drug - Pancreatic Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Qualigen
Company Location:
Company CEO:
Additional Commercial Interests: UCL University College London
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Qualigen presented P1 Pancreatic Cancer results on 2024-04-05 for QN-302
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06086522 |
302P1V01 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-12-01 |
67% |
2024-05-02 |
Primary Endpoints|Treatments |